Related Experiment Video
Updated: Apr 14, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica
Shanthi Viswanathan1, Anna H Y Wong2, Amy M L Quek2
1Department of Neurology, Kuala Lumpur Hospital, Malaysia.
Objectives:
To evaluate the use of intravenous immunoglobulin (IVIG) in preventing relapses in patients with neuromyelitis optica (NMO) and its spectrum disorders (NMOSDs).
Methods:
Six NMO/NMOSD patients who were treated with IVIG induction dose followed by 2- to 3- monthly infusions were retrospectively identified. Annualized relapse rates (ARR) and Expanded Disability Status Scale (EDSS) pre- and post-IVIG were recorded.
Results:
Median number of relapses and median ARR significantly reduced from 8.0 to 1.0 and 0.75 to 0.15 (p<0.05) respectively. Median EDSS of 6.5 remained the same. Median duration of treatment was 4.0 years.
Conclusion:
IVIG may be used to reduce the relapse frequency in patients with NMO/NMOSD.
More Related Videos
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

